These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 28533357)
1. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357 [TBL] [Abstract][Full Text] [Related]
2. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142 [TBL] [Abstract][Full Text] [Related]
3. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794 [TBL] [Abstract][Full Text] [Related]
4. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Kortylewski M; Moreira D Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929 [TBL] [Abstract][Full Text] [Related]
5. ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer. Chen H; Yang K; Pang L; Fei J; Zhu Y; Zhou J J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822671 [TBL] [Abstract][Full Text] [Related]
6. Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment. Fu SY; Chen FH; Wang CC; Yu CF; Chiang CS; Hong JH Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1547-1558. PubMed ID: 33188861 [TBL] [Abstract][Full Text] [Related]
7. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of Ly6G Heim CE; West SC; Ali H; Kielian T Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249747 [TBL] [Abstract][Full Text] [Related]
9. Visualization and quantification of Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525 [TBL] [Abstract][Full Text] [Related]
10. Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice. Kawano T; Shimamura M; Nakagami H; Kanki H; Sasaki T; Mochizuki H PLoS One; 2019; 14(5):e0215482. PubMed ID: 31048856 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081 [TBL] [Abstract][Full Text] [Related]
12. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients. Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B Front Immunol; 2020; 11():613215. PubMed ID: 33679700 [TBL] [Abstract][Full Text] [Related]
13. DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC. Liu W; Zhang F; Quan B; Yao F; Chen R; Ren Z; Dong L; Yin X Cell Mol Gastroenterol Hepatol; 2024; 18(4):101377. PubMed ID: 38969205 [TBL] [Abstract][Full Text] [Related]
14. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression. Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833 [TBL] [Abstract][Full Text] [Related]
15. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279 [TBL] [Abstract][Full Text] [Related]